Williams Cancer Institute



As I had mentioned earlier in this book, I saw a poster presentation at the 2017 SITC by Lennicke, et al. that described how supplementing with selenium could help patients who begin failing PD-1 inhibitors to respond again. There is much in the literature describing the anti-cancer and cancer prevention properties of selenium. However, as I did further research, I discovered that there are a few things to consider. The main supplemental forms of selenium is selenomethionine (SeMet) and, occasionally, selenium-methyl L-selenocysteine. When I reviewed the literature, the more significant effects are seen with methylseleninic acid (MSA). However, I have been unable to locate this in supplement form. Yan, et al. published a study titled “Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice.” It does seem there may be some conversion inside the body from SeMet to MSA, but the studies I read still show that the results are inferior. So, for the time being, it seems selenomethionine may be the best option, until maybe MSA becomes available. Lennicke, et al., published another study in Oncoim- munology, Dec 2016 “Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid (MSA).” They describe that MSA may increase MHC I expression in tumor cells, which blocks a method that cancer can use to escape the immune response. In addition, MSA seems to have other immune-stimulating effects that decrease regulatory cells and many immune inhibitor substances, like VEGF and PDGF.

Reference: Jason R. Williams, 15 Oct 2019, The Immunotherapy Revolution: The Best New Hope For Saving Cancer Patients’ Lives, https://williamscancerinstitute.com/the-immunotherapy-revolution

Related Posts

Blog 18 de Julio de 2024
Blog 16 de Julio de 2024
bLog 11 de Julio de 2024
1 2 3 117